AIM

Companies
Nyse American
Aim Immunotech Inc.
Health Care
Price Chart
Overview

About AIM

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Market Cap
$24.3M
Volume
4.8M
Avg. Volume
7.0M
P/E Ratio
-0.2314634
Dividend Yield
0.00%
Employees
25.0

Company Information

Exchange
Nyse American
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.48
Low Correlation
Volatility
High (0.92)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for AIM.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, AIM shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$24.3M
Volume4.8M
P/E Ratio-0.23
Dividend Yield0.00%
Important Dates
Next Dividend
June 11, 2019
Next Earnings
March 27, 2025
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how AIM fits into your investment strategy and portfolio diversification.

Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025